ArticleIntestinal research2017
Fecal microbiota transplantation for refractory Crohn's disease.
Article in Intestinal research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 33 citations in OpenAlex.
- Fecal microbiota transplantation for Crohn's disease: a systematic review and meta-analysis.Techniques in coloproctology · 2021Pooled it
- The Safety of Fecal Microbiota Transplantation for Crohn's Disease: Findings from A Long-Term Study.Advances in therapy · 2018Trial
- Role and mechanism of gut microbiota-host interactions in the pathogenesis of Crohn's disease.International journal of colorectal disease · 2025Review
- Current Trends and Challenges of Fecal Microbiota Transplantation-An Easy Method That Works for All?Biomedicines · 2022Review
- Alteration of microbiota antibody-mediated immune selection contributes to dysbiosis in inflammatory bowel diseases.EMBO molecular medicine · 2022Article
- Gut microbiota: A new target for T2DM prevention and treatment.Frontiers in endocrinology · 2022Review
- Bibliometric and visual analysis of fecal microbiota transplantation research from 2012 to 2021.Frontiers in cellular and infection microbiology · 2022Article
- Oral nanomedicine for modulating immunity, intestinal barrier functions, and gut microbiome.Advanced drug delivery reviews · 2021Review
- Management of Clostridioides difficile infection in patients with inflammatory bowel disease.Intestinal research · 2021Review
- Secondary causes of inflammatory bowel diseases.World journal of gastroenterology · 2020Review
- Development of the Korean Form of the Premonitory Urge for Tics Scale: A Reliability and Validity Study.Soa--ch'ongsonyon chongsin uihak = Journal of child & adolescent psychiatry · 2020Article
- Alteration of Gut Microbiota in Autism Spectrum Disorder: An Overview.Soa--ch'ongsonyon chongsin uihak = Journal of child & adolescent psychiatry · 2020Review
- The microbiome, cancer, and cancer therapy.Nature medicine · 2019Review
- RecurrentGut and liver · 2019Review
- Low diversity gut microbiota dysbiosis: drivers, functional implications and recovery.Current opinion in microbiology · 2018Review
- Fecal transplantation: digestive and extradigestive clinical applications.Clujul medical (1957) · 2018Review
- Microbiota transplantation: concept, methodology and strategy for its modernization.Protein & cell · 2018Review
- Is there a potential role of fecal microbiota transplantation in the treatment of inflammatory bowel disease?Intestinal research · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Approximately one-third of patients with Crohn's disease do not respond to conventional treatments, and some experience significant adverse effects, such as serious infections and lymphoma, and many patients require surgery due to complications. Increasing evidence suggests that specific changes in the composition of gut microbiota, termed as dysbiosis, are a common feature in patients with inflammatory bowel disease (IBD). Dysbiosis can lead to activation of the mucosal immune system, resulting in chronic inflammation and the development of mucosal lesions. Recently, fecal microbiota transplantation, aimed at modifying the composition of gut microbiota to overcome dysbiosis, has become a potential alternative therapeutic option for IBD. Herein, we present a patient with Crohn's colitis in whom biologic therapy failed previously, but clinical remission and endoscopic improvement was achieved after a single fecal microbiota transplantation infusion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.